H. Fleury

C. Sergeant, H. Fleury, J. Pellegrin, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients.

H. Fleury, D. Ekouevi, G. Chêne, 2000, The Journal of infectious diseases.

Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients

A. Ferrer, J. Ragnaud, H. Fleury, 1997, Journal of clinical microbiology.

Detection of JC virus DNA in the peripheral blood leukocytes of HIV‐infected patients

J. Ragnaud, H. Fleury, J. Pellegrin, 1996, AIDS.

HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaoundé, Cameroon.

H. Fleury, F. Barré-Sinoussi, A. Ayouba, 2006, Journal of acquired immune deficiency syndromes.

Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures.

B. Masquelier, D. Neau, J. Ragnaud, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions

L. Stuyver, B. Masquelier, H. Fleury, 2010, PloS one.

Foscarnet decreases HIV-1 plasma load.

D. Breilh, J. Ragnaud, M. Dupon, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Novel C-organosilicon derivatives as leads for reverse-transcriptase-mediated anti-HIV-1 activity

J. Lafay, H. Fleury, G. Déléris, 1996 .

Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.

R. Salamon, B. Masquelier, F. Dabis, 2002, AIDS.

Value of influenza vaccine during an outbreak of influenza A in a nursing home, Pyrenees Atlantiques, France, November-December 1995.

J. Desenclos, H. Fleury, A. Infuso, 1996, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Vascular endothelial growth factor (VEGF165) plasma level increase with immunodepression in AIDS patients with Kaposi's sarcoma.

M. Dupon, H. Fleury, J. Viallard, 1999, Microvascular research.

Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia

H. Fleury, P. Trimoulet, H. Triki, 2014, Journal of medical virology.

FURTHER ULTRASTRUCTURAL OBSERVATIONS OF VIRUS MORPHOGENESIS AND MYELIN PATHOLOGY IN JHM VIRUS ENCEPHALOMYELITIS

H. Fleury, C. Raine, M. Bornstein, 1980, Neuropathology and applied neurobiology.

In vitro infection of human macrophages with human T-cell leukemia virus type 1.

H. Fleury, P. Roques, D. Dormont, 1993, Blood.

Methicillin-resistant Staphylococcus aureus with the novel mecC gene variant isolated from a cat suffering from chronic conjunctivitis

S. Yerly, H. Fleury, D. Descamps, 2013 .

Biochemical characterization of a Yucaipa-like virus.

M. Monsion, H. Fleury, P. Du Pasquier, 1980, The Journal of general virology.

Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naive to antiretroviral drugs.

H. Fleury, P. Glaziou, J. Reynes, 2005, AIDS research and human retroviruses.

Quantitation of Hepatitis C Virus RNA in Plasma and Peripheral Blood Mononuclear Cells of Patients with Chronic Hepatitis Treated with Interferon-α

V. de Lédinghen, P. Couzigou, H. Fleury, 2004, Digestive Diseases and Sciences.

Human polyomavirus JC latency and reactivation status in blood of HIV-1-positive immunocompromised patients with and without progressive multifocal leukoencephalopathy.

H. Fleury, L. Andréoletti, V. Dubois, 1999, AIDS.

JC virus remains latent in peripheral blood B lymphocytes but replicates actively in urine from AIDS patients.

J. Ragnaud, H. Fleury, J. Pellegrin, 1998, The Journal of infectious diseases.

One-year antioxidant supplementation with beta-carotene or selenium for patients infected with human immunodeficiency virus: a pilot study.

C. Sergeant, H. Fleury, J. Pellegrin, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Isolation of twenty-three Yucaipa-like viruses from 616 wild birds in Senegal, West Africa.

H. Fleury, D. Alexander, 1979, Avian diseases.

First isolation of a Yucaipa-like virus in Africa.

H. Fleury, 1978, Avian diseases.

Antigenic and biological characterisation of avian paramyxovirus type I isolates from pigeons--an international collaborative study.

H. Fleury, E. Kaleta, P. Russell, 1985, Avian pathology : journal of the W.V.P.A.

Isolation of paramyxoviruses of the PMV-1 serotype from pigeons captured in the city of Bordeaux

H. Fleury, P. Pasquier, M. Babín, 1984 .

Susceptibility of the guinea-pig to Paramyxovirus Yucaipa

H. Fleury, P. Pasquier, M. Babín, 1983 .

Comparison of the structural polypeptides of the american and african strains of Paramyxovirus Yucaipa

H. Fleury, P. Pasquier, J. Leclerc, 1981 .

Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.

B. Masquelier, H. Fleury, O. Cosnefroy, 2010, The Journal of antimicrobial chemotherapy.

Probable Sexually Transmitted Zika Virus Infection in a Pregnant Woman.

X. de Lamballerie, H. Fleury, D. Malvy, 2018, The New England journal of medicine.

Replicationd Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in

V. Calvez, P. Harrigan, H. Fleury, 2014 .

Replication Maraviroc-Treated Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in

V. Calvez, P. Harrigan, H. Fleury, 2013 .

HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication

V. Calvez, P. Harrigan, B. Masquelier, 2012, Antimicrobial Agents and Chemotherapy.

Further characterization of HIV-1 isolates from Ho Chi Minh City, Vietnam.

B. Masquelier, H. Fleury, T. V. Nguyen, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Lamivudine therapy of chronic hepatitis B in three groups of patients: non transplanted patients, liver recipients, and kidney recipients.

V. de Lédinghen, P. Couzigou, H. Fleury, 2002, Gastroenterologie clinique et biologique.

Anti‐hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV‐infected patients

C. Katlama, G. Le Teuff, H. Fleury, 2006, Hepatology.

HIV‐1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation

B. Masquelier, J. Ragnaud, M. Dupon, 2006, HIV medicine.

Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients.

H. Fleury, M. Essig, S. Alain, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Plasma and Liver Hepatitis C Virus Variability in Patients Coinfected with Human Immunodeficiency Virus

D. Neau, J. Ragnaud, M. Dupon, 2006, Journal of Clinical Microbiology.

Human Immunodeficiency Virus Variability in Patients Coinfected with Plasma and Liver Hepatitis C Virus

D. Neau, J. Ragnaud, M. Dupon, 2006 .

Prolonged shedding of influenza A(H1N1)v virus: two case reports from France 2009.

M. Dupon, H. Fleury, S. Burrel, 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004.

V. de Lédinghen, P. Couzigou, D. Neau, 2007, Gastroenterologie clinique et biologique.

HEPATITIS B VIRUS GENOTYPES: A RETROSPECTIVE SURVEY IN SOUTHWESTERN FRANCE, 1999-2004 ETUDE RETROSPECTIVE DES GENOTYPES DU VIRUS DE L'HEPATITE B EN AQUITAINE, 1999-2004

P. Couzigou, D. Neau, J. Ragnaud, 2007 .

Comparison of the immunoglobulin-G-specific seroreactivity of different recombinant antigens of the human herpesvirus 8.

B. Masquelier, H. Fleury, F. Neipel, 1999, Virology.

Impact of protease inhibitors on intrahepatic hepatitis C virus viral load.

D. Neau, J. Ragnaud, M. Dupon, 2001, AIDS.

Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.

H. Fleury, F. Raffi, C. Michelet, 2002, The Journal of infectious diseases.

Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up

D. Raoult, H. Fleury, C. Mengelle, 2004, Journal of Clinical Microbiology.

In vitro photochemical inactivation of cell‐associated human T‐cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen

H. Fleury, B. Guillemain, K. Dupuis, 2005, Transfusion.

Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients.

H. Fleury, C. Dromer, A. Caumont, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

PCR-detected hepatitis C virus RNA associated with human zona-intact oocytes collected from infected women for ART.

H. Fleury, P. Trimoulet, A. Papaxanthos-Roche, 2004, Human reproduction.

Isolation of an adeno-like virus from two cases of strawberry disease in rainbow trout

H. Fleury, E. Sochon, A. Vuillaume, 1985 .

A comparison of the fatty acids of four measles and SSPE viruses

H. Fleury, P. Pasquier, M. Babín, 1983 .

1155 Efficacy of tenofovir disoproxil fumarate (TDF) for hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infected patients

C. Katlama, Y. Yazdanpanah, D. Neau, 2003 .

Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient.

D. Neau, J. Ragnaud, H. Fleury, 2000, The Journal of infection.

Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

P. Couzigou, J. Ragnaud, M. Dupon, 1996, BMJ.

Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.

F. Ceccherini‐Silberstein, H. Fleury, F. Mazzotta, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.

M. Houghton, D. Neau, J. Ragnaud, 2002, The Journal of infectious diseases.

Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients

D. Breilh, D. Neau, F. Dabis, 2007, Antimicrobial Agents and Chemotherapy.

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

B. Masquelier, D. Breilh, D. Neau, 2010, The Journal of antimicrobial chemotherapy.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro

Domenico Di Carlo, F. Ceccherini‐Silberstein, H. Fleury, 2017, Oncotarget.

Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2001, Antimicrobial Agents and Chemotherapy.

Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.

B. Berkhout, H. Fleury, M. Andreoni, 2015, The Journal of infection.

Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003.

D. Neau, J. Ragnaud, M. Dupon, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.

F. Ceccherini‐Silberstein, H. Fleury, M. Levrero, 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia

H. Fleury, P. Trimoulet, H. Triki, 2015, Virology Journal.

HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets

F. Ceccherini‐Silberstein, H. Fleury, M. Andreoni, 2018, Viruses.

Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy

Rodolphe Thiébaut, François Dabis, Philippe Morlat, 2008, AIDS.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

A European multicenter study on the analytical performance of the VERIS HBV assay.

A. Lombardi, H. Fleury, J. Izopet, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Presence of HIV-1 CRF35_AD in Iran.

H. Fleury, P. Pinson, M. Zadsar, 2009, AIDS research and human retroviruses.

Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia

H. Fleury, P. Trimoulet, H. Triki, 2015, Virology Journal.

Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin

J. Pawlotsky, H. Fleury, G. Duverlie, 2015, Journal of Clinical Microbiology.

Dynamic and Rapid Changes in Viral Quasispecies by Udps in Chronic Hepatitis C Patients Receiving Telaprevir-Based Therapy

V. de Lédinghen, H. Fleury, M. Kann, 2013, Antiviral therapy.

Virological Responses to Atazanavir–Ritonavir-Based Regimens: Resistance-Substitutions Score and Pharmacokinetic Parameters (Reyaphar Study)

D. Breilh, D. Neau, J. Ragnaud, 2005, Antiviral therapy.

Characterization of HIV-1 isolates from antiretroviral drug-naive children in southern India.

S. Swaminathan, H. Fleury, R. Ramachandran, 2007, AIDS research and human retroviruses.

Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy

V. de Lédinghen, P. Couzigou, H. Fleury, 2004, Journal of medical virology.

Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014

F. Dabis, H. Fleury, E. Lazaro, 2015, Open forum infectious diseases.

Virological Response to Darunavir/Ritonavir-Based Regimens in Antiretroviral-Experienced Patients (PREDIZISTA Study)

D. Breilh, D. Neau, H. Fleury, 2008, Antiviral therapy.

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study)

D. Breilh, H. Fleury, H. Budzinski, 2004, AIDS.

Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease

B. Masquelier, H. Fleury, C. Rouzioux, 1996 .

Intrahepatic HCV RNA loads in 37 HIV‐HCV co‐infected patients with controlled HIV infection

D. Neau, J. Ragnaud, M. Dupon, 2002, Journal of medical virology.

Human herpesvirus 8 variants in Venezuelan patients with AIDS-related Kaposi sarcoma.

B. Masquelier, H. Fleury, D. Hernåndez, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Study of human herpesvirus 8 (HHV-8) variants from Kaposi's sarcoma in France: is HHV-8 subtype A responsible for more agressive tumors?

B. Masquelier, J. Ragnaud, M. Dupon, 1998, The Journal of infectious diseases.

Necrotic Ulcerated Lesion in a Young Boy Caused by Cowpox Virus Infection

H. Fleury, S. Lepreux, F. Boralevi, 2011, Case Reports in Dermatology.

Stimulation of the Human RAD51 Nucleofilament Restricts HIV-1 Integration In Vitro and in Infected Cells

P. Sung, H. Fleury, E. Le Cam, 2011, Journal of Virology.

Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease

J. Laplanche, H. Fleury, P. Tiberghien, 2016, Science Translational Medicine.

Variability and recombination of clinical human cytomegalovirus strains from transplantation recipients.

J. Velly, H. Fleury, C. Dromer, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Variability of UL18, UL40, UL111a and US3 immunomodulatory genes among human cytomegalovirus clinical isolates from renal transplant recipients.

H. Fleury, J. Déchanet-Merville, I. Garrigue, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Epidemiological and phylogenetic evidence for patient‐to‐patient hepatitis C virus transmission during sclerotherapy of varicose veins

V. de Lédinghen, P. Couzigou, H. Fleury, 2005, Journal of medical virology.

Analysis of HIV-1 expression in vivo with in situ hybridization and the polymerase chain reaction.

J. Ragnaud, H. Fleury, J. Seigneurin, 1992, Molecular and cellular probes.

Hepatitis C virus (HCV) protease variability and anti‐HCV protease inhibitor resistance in HIV/HCV‐coinfected patients

D. Neau, J. Ragnaud, M. Dupon, 2011, HIV medicine.

Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure

B. Masquelier, D. Neau, P. Morlat, 2014, PloS one.

Progression to AIDS or Death as Endpoints in HIV Clinical Trials

H. Fleury, F. Raffi, C. Leport, 2001, HIV clinical trials.

Tickborne encephalitis, southwestern France.

H. Fleury, H. Zeller, D. Malvy, 2007, Emerging infectious diseases.

TT virus infection during chronic hepatitis C

P. Couzigou, H. Fleury, D. Ekouevi, 2000, American Journal of Gastroenterology.

Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals

H. Fleury, A. Aubertin, A. Kirn, 1997, Journal of virology.

HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs.

B. Masquelier, H. Fleury, P. Roques, 2003, AIDS research and human retroviruses.

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

Anne-Mieke Vandamme, Soo-Yon Rhee, Tommy F. Liu, 2009, PloS one.

Hepatitis C Virus Genotyping Based on 5′ Noncoding Sequence Analysis (Trugene)

V. de Lédinghen, P. Couzigou, D. Ouzan, 2001, Journal of Clinical Microbiology.

Noncoding Sequence Analysis ( Trugene ) ′ Hepatitis C Virus Genotyping Based on 5

P. Couzigou, D. Ouzan, H. Fleury, 2001 .

Cross-clade conservation of HIV type 1 Nef immunodominant regions recognized by CD8+ T cells of HIV type 1 CRF02_AG-infected Ivorian (West Africa).

H. Fleury, J. Guillet, A. Minga, 2005, AIDS research and human retroviruses.

Seven nucleotide changes characteristic of the hepatitis C virus genotype 3 5' untranslated region: correlation with reduced in vitro replication.

H. Fleury, P. Trimoulet, A. Cahour, 2008, The Journal of general virology.

Kinetics of HIV-1 CTL Epitopes Recognized by HLA I Alleles in HIV-Infected Individuals at Times near Primary Infection: The Provir/Latitude45 Study

M. Wainberg, J. Routy, H. Fleury, 2014, PLoS ONE.

Resistance Mutations and CTL Epitopes in Archived HIV-1 DNA of Patients on Antiviral Treatment: Toward a New Concept of Vaccine

D. Neau, H. Fleury, E. Lazaro, 2013, PloS one.

Sequences of clustered epitopes in Gag and Nef potentially presented by predominant class I human leukocyte antigen (HLA) alleles A and B expressed by human immunodeficiency virus type 1 (HIV-1)-infected patients in Vietnam.

P. Debré, H. Fleury, E. Lazaro, 2005, AIDS research and human retroviruses.

Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients.

D. Neau, J. Ragnaud, M. Dupon, 1997, AIDS research and human retroviruses.

Evaluation of the VERSANT HCV RNA 3.0 Assay for Quantification of Hepatitis C Virus RNA in Serum

H. Fleury, G. Chêne, P. Trimoulet, 2002, Journal of Clinical Microbiology.

Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: a 2005 study.

H. Fleury, A. Ayouba, V. Maréchal, 2006, AIDS research and human retroviruses.

Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals.

H. Fleury, P. Bellecave, S. Reigadas, 2014, AIDS research and human retroviruses.

Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.

H. Fleury, P. Massip, J. Puel, 1999, AIDS.

Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS medicine.

In vitro assays show a dissociation of reverse transcriptase activity and core antigen (p24) production in two HIV-1 isolates from a patient receiving long-term treatment with zidovudine (ZDV).

B. Masquelier, H. Fleury, J. Pellegrin, 1991, Journal of acquired immune deficiency syndromes.

Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.

J. Ragnaud, M. Dupon, H. Fleury, 2003, The Journal of infectious diseases.

Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.

B. Masquelier, H. Fleury, E. Lazaro, 2005, AIDS research and human retroviruses.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

D. Katzenstein, N. Ford, R. Shafer, 2013, The Journal of infectious diseases.

Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/µl? Impact on immunovirological parameters

H. Fleury, J. Moreau, J. Viallard, 2005, Journal of medical virology.

Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 × 106 cells/l

H. Fleury, J. Moreau, J. Viallard, 2005, AIDS.

First data on HIV-1 resistance mutations to antiretroviral drugs in Central African Republic.

H. Fleury, P. Pinson, J. Gody, 2010, AIDS research and human retroviruses.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Jerome H. Kim, J. Ioannidis, D. Katzenstein, 2015, PLoS medicine.

Sequence analysis of env C2/V3, gag p17/p24, and pol protease regions of 25 HIV type 1 isolates from Ho Chi Minh City, Vietnam.

H. Fleury, F. Barré-Sinoussi, P. Roques, 2001, AIDS research and human retroviruses.

Multiclass Primary Antiretroviral Drug Resistance in a Patient Presenting HIV-1/2 Dual Infection

M. Cavassini, H. Fleury, P. Recordon-Pinson, 2012, Antiviral therapy.

Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.

H. Fleury, P. Glaziou, J. Reynes, 2007, AIDS research and human retroviruses.

Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 study.

R. Salamon, B. Masquelier, F. Dabis, 2003, AIDS research and human retroviruses.

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

R. Salamon, F. Brun-Vézinet, C. Katlama, 2017, The Journal of antimicrobial chemotherapy.

Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA

H. Fleury, B. Hoen, I. Pellegrin, 2000, AIDS.

Heterosexual transmission of Kaposi's sarcoma-associated herpes virus between two patients developing AIDS-Kaposi's sarcoma.

B. Masquelier, M. Dupon, H. Fleury, 2000, AIDS.

Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.

B. Masquelier, H. Fleury, C. Rouzioux, 2001 .

Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?

A. Fischer, R. Tubiana, L. Cravello, 2020, The Journal of antimicrobial chemotherapy.

Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.

B. Masquelier, D. Neau, J. Ragnaud, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Molecular Characterization of HIV-1 CRF01_AE in Mekong Delta, Vietnam, and Impact of T-Cell Epitope Mutations on HLA Recognition (ANRS 12159)

H. Fleury, E. Lazaro, P. Bellecave, 2011, PloS one.

[Comparative study of the prevalence of Herpesviridae in an African population and a European population].

H. Fleury, A. Samb, M. Babín, 1985, Bulletin de la Societe de pathologie exotique et de ses filiales.

Improvement of Progressive Multifocal Leukoencephalopathy After Cidofovir Therapy in a Patient with a Destructive Polyarthritis

H. Fleury, H. Fleury, E. Lazaro, 2007, Infection.

UL40 Human Cytomegalovirus Variability Evolution Patterns Over Time in Renal Transplant Recipients

H. Fleury, J. Déchanet-Merville, J. Taupin, 2008, Transplantation.

Activation of GCN2 upon HIV-1 infection and inhibition of translation

H. Fleury, A. Jaspart, C. Calmels, 2013, Cellular and Molecular Life Sciences.

Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR.

B. Masquelier, H. Fleury, P. Pinson, 2007, AIDS research and human retroviruses.

Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data.

B. Masquelier, H. Fleury, E. Lazaro, 2006, AIDS research and human retroviruses.

High diversity of HIV type 1 in Algeria.

H. Fleury, I. Garrigue, P. Recordon-Pinson, 2006, AIDS Research and Human Retroviruses.

HIV type 1 Thai subtype E is predominant in South Vietnam.

H. Fleury, F. Barré-Sinoussi, M. Müller-Trutwin, 1996, AIDS research and human retroviruses.

Predominance of CRF06_cpx and Transmitted HIV Resistance in Algeria: Update 2013-2014.

H. Fleury, P. Recordon-Pinson, J. Papuchon, 2016, AIDS research and human retroviruses.

Presence of drug resistance mutations among drug-naive patients in Morocco.

H. Fleury, H. Annaz, S. Mrani, 2011, AIDS research and human retroviruses.

First observation of HIV type 1 drug resistance mutations in Algeria.

B. Masquelier, H. Fleury, P. Pinson, 2008, AIDS research and human retroviruses.

Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis.

H. Fleury, A. Caumont, I. Pellegrin, 2001, Journal of virological methods.

Association between IgM Anti-Herpes Simplex Virus and Plasma Amyloid-Beta Levels

L. Buée, J. Dartigues, L. Letenneur, 2011, PloS one.

A highly virulent togavirus-like agent associated with the fulminating disease of guinea fowl.

H. Fleury, A. Brahem, A. Vuillaume, 1992, Avian diseases.

Screening for HIV in necropsies.

M. Dupon, H. Fleury, J. Lacut, 1989, BMJ.

Seropositivity to Herpes Simplex Virus Antibodies and Risk of Alzheimer's Disease: A Population-Based Cohort Study

P. Barberger‐Gateau, S. Gauthier, J. Dartigues, 2008, PloS one.

Fatal Case of Enterovirus 71 Infection and Rituximab Therapy, France, 2012

H. Fleury, B. Lina, A. Boyer, 2013, Emerging infectious diseases.

Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010.

H. Fleury, E. Bessède, H. Rozé, 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006.

R. Salamon, B. Masquelier, F. Dabis, 2007, AIDS research and human retroviruses.

Presence of CRF09_cpx and complex CRF02_AG/CRF09_cpx recombinant HIV type 1 strains in Côte d'Ivoire, West Africa.

John Nkengasong, Martine Peeters, Monica Nolan, 2005, AIDS research and human retroviruses.

Estimating HIV-1 Genetic Diversity in Brazil Through Next-Generation Sequencing

M. Soares, H. Fleury, S. Sanabani, 2019, Front. Microbiol..

Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003

D. Pillay, G. Poggensee, B. Masquelier, 2005, Journal of acquired immune deficiency syndromes.

ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)

P. Morlat, H. Fleury, P. Thébault, 2020, Viruses.

Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro.

H. Fleury, C. Spenlehauer, F. Letourneur, 1997, AIDS research and human retroviruses.

HIV-1 diversity in France, 1996–1998

F. Brun-Vézinet, H. Fleury, P. Roques, 2000 .

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)

V. Calvez, C. Charpentier, C. Delaugerre, 2018, The Journal of antimicrobial chemotherapy.

Activation of GCN2 upon HIV-1 infection and inhibition of translation

H. Fleury, A. Jaspart, C. Calmels, 2013, Cellular and Molecular Life Sciences.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Re-evaluation of anti-HBc non-reactive serum samples from patients with persistent hepatitis B infection by immune precipitation with labelled HBV core antigen.

H. Fleury, M. Kann, W. Gerlich, 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco.

H. Fleury, S. Mrani, H. El Annaz, 2012, AIDS research and human retroviruses.

Novel variant of the CCR5 gene in a Vietnamese population.

P. Debré, H. Fleury, F. Barré-Sinoussi, 1999, Microbes and infection.

Infection chronique à virus influenza chez un patient traité par alemtuzumab

H. Fleury, S. Burrel, N. Milpied, 2010 .

[Persistent influenza virus infection in a patient treated with alemtuzumab].

H. Fleury, S. Burrel, N. Milpied, 2010, Medecine et maladies infectieuses.

Study of the V3 Loop as a Target Epitope for Antibodies Involved in the Neutralization of Primary Isolates versus T-Cell-Line-Adapted Strains of Human Immunodeficiency Virus Type 1

H. Fleury, C. Spenlehauer, A. Aubertin, 1998, Journal of Virology.

A European multicientre study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBAS® TAQMAN® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens VERSANT HIV-1 Assay.

A. Lombardi, H. Fleury, J. Izopet, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

European Multicenter Study on Analytical Performance of Veris HIV-1 Assay

A. Lombardi, H. Fleury, J. Izopet, 2017, Journal of Clinical Microbiology.

Phylogenetic analysis of HIV-1 archived DNA in blood and gut-associated lymphoid tissue in two patients under antiretroviral therapy

J. Routy, H. Fleury, A. Gosselin, 2021, Gut Pathogens.

Nucleic acid amplification testing detection of an HIV‐1 infection in a blood donor during the preseroconversion window period

D. Neau, H. Fleury, S. Laperche, 2007, Transfusion medicine.

HIV-1 and HCV co-infected patients: detection of active viral expression using a nested polymerase chain reaction.

H. Fleury, J. Pellegrin, B. Leng, 1993, Molecular and cellular probes.

Detection of Human Immunodeficiency Virus Type 1 Antiretroviral Resistance Mutations by High-Density DNA Probe Arrays

B. Masquelier, H. Fleury, G. Vernet, 2004, Journal of Clinical Microbiology.

POSSIBLE INVOLVEMENT OF HIV IN NEUROPSYCHIATRIC EPISODE IN PATIENT SERONEGATIVE FOR TWO (OR MORE) YEARS

H. Fleury, D. Dormont, P. Brunet, 1987, The Lancet.

Acute hepatitis associated with hepatitis G virus primo-infection in a renal transplant recipient.

H. Fleury, P. Trimoulet, P. Merville, 2004, Transplantation.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)

D. Breilh, P. Morlat, H. Fleury, 2002, AIDS.

Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.

H. Fleury, J. Pellegrin, A. Caumont, 2001, AIDS.

A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit.

A. Lombardi, H. Fleury, J. Izopet, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance

Jerome H. Kim, M. Poljak, R. Shafer, 2015 .

HIV and SARS-CoV-2 Pathogenesis and Vaccine Development

H. Fleury, 2022, Viruses.

Plasma Interferon α and the Wasting Syndrome in Patients Infected with the Human Immunodeficiency Virus

C. Sergeant, H. Fleury, J. Pellegrin, 1995 .

Phylogenetic analysis of HIV-1 archived DNA in blood and gut-associated lymphoid tissue in patients receiving antiretroviral therapy: a study from Provir/Latitude45 project

M. Soares, J. Routy, H. Fleury, 2020, bioRxiv.

Cervical human papillomavirus and HIV infection in women of child-bearing age in Abidjan, Côte d’Ivoire, 2010

A. Sasco, F. Dabis, H. Fleury, 2012, British Journal of Cancer.

Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).

D. Breilh, H. Fleury, S. Djabarouti, 2006, The Journal of antimicrobial chemotherapy.

Structure-Analysis of the HIV-1 Integrase Y143C/R Raltegravir Resistance Mutation in Association with the Secondary Mutation T97A

M. Laguerre, B. Masquelier, D. Neau, 2011, Antimicrobial Agents and Chemotherapy.

Structure analysis of HIV-1 IN Y143C/R Raltegravir resistance mutation in association

C. Calmels, H. Fleury, M. Laguerre, 2011 .

Sanger and Next-Generation Sequencing data for characterization of CTL epitopes in archived HIV-1 proviral DNA

H. Fleury, P. Bellecave, P. Recordon-Pinson, 2017, PloS one.

Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.

D. Breilh, D. Neau, J. Ragnaud, 2009, Journal of acquired immune deficiency syndromes.

HIV Type-1 Transmission Dynamics in Recent Seroconverters: Relationship with Transmission of drug Resistance and Viral Diversity

B. Masquelier, D. Neau, P. Morlat, 2008, Antiviral therapy.

CMV plasma DNAemia and risk of cancer among HIV-infected patients: a case-control study nested in the ANRS CO3 Aquitaine Cohort, France, 2002-2007.

M. Dupon, F. Dabis, H. Fleury, 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.

H. Fleury, P. Pinson, A. Deshpande, 2010, AIDS research and human retroviruses.

Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.

J. Ragnaud, H. Fleury, B. Hoen, 1999, The Journal of infectious diseases.

Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India.

H. Fleury, P. Recordon-Pinson, S. Karki, 2011, AIDS research and human retroviruses.

Phylogenetic analysis of HIV-1 reverse transcriptase sequences from 382 patients recruited in JJ Hospital of Mumbai, India, between 2002 and 2008.

H. Fleury, P. Pinson, A. Deshpande, 2009, AIDS research and human retroviruses.

Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations.

H. Fleury, M. Faure, I. Garrigue, 2004, AIDS research and human retroviruses.

HIV-1 transmission during scintigraphy

B. Masquelier, M. Dupon, H. Fleury, 2003, The Lancet.

European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay

Jordi Vila, Patrick Braun, Rafael Delgado, 2017, Journal of Clinical Microbiology.

Molecular characterization of HIV type 1 in Brazzaville, Republic of Congo, and first data on resistance to antiretroviral drugs.

H. Fleury, P. Recordon-Pinson, B. Simon, 2012, AIDS research and human retroviruses.

Establishment of a national network of validated and qualified laboratories for neutralizing anti-vaccinia antibodies titration.

H. Fleury, F. Fuchs, I. Leparc-Goffart, 2005, Biologicals (Print).

Dried cervical spots for human papillomaviruses identification

F. Dabis, H. Fleury, A. Minga, 2013, Journal of medical virology.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

S. Yerly, B. Masquelier, H. Fleury, 2013, The Journal of antimicrobial chemotherapy.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

V. Calvez, C. Charpentier, P. André, 2018, The Journal of antimicrobial chemotherapy.

Pharmacokinetics and Resistance Mutations Affect Virologic Response to Ritonavir/Saquinavir-Containing Regimens

D. Breilh, D. Neau, H. Fleury, 2001, Therapeutic drug monitoring.

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.

B. Masquelier, H. Fleury, F. Raffi, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions

H. Fleury, C. Nguyen, V. Dollé, 1999, Archives of Virology.

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

C. Fagard, B. Masquelier, D. Breilh, 2009, The Journal of antimicrobial chemotherapy.

Surveillance of HIV type 1 drug resistance among naive patients from Venezuela.

B. Masquelier, H. Fleury, P. Pinson, 2009, AIDS research and human retroviruses.

Molecular characterization, phylogenetic relationships, and developmental expression patterns of prion genes in zebrafish (Danio rerio)

H. Fleury, P. J. Babin, M. André, 2005, The FEBS journal.

Influenza B burden during seasonal influenza epidemics in France.

H. Fleury, B. Lina, S. van der Werf, 2017, Medecine et maladies infectieuses.

Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.

B. Masquelier, M. Dupon, F. Dabis, 2006, Journal of Clinical Virology.

Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.

R. Tubiana, C. Katlama, H. Fleury, 1997, AIDS.

Predominance of CCR5-dependent HIV-1 subtype E isolates in Cambodia.

V. Trouplin, H. Fleury, F. Barré-Sinoussi, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Perinatal HIV infection: longitudinal study of 22 children (clinical and biological follow-up)

H. Fleury, Y. Pérel, M. Micheau, 1989, Journal of acquired immune deficiency syndromes.

REPLICATION OF MEASLES VIRUS IN A CELL CULTURE FROM A GLIOBLASTOMA OF HUMAN ORIGIN

H. Fleury, P. Pasquier, 1977, Journal of neuropathology and experimental neurology.

Oseltamivir susceptibility in south-western France during the 2007-8 and 2008-9 influenza epidemics and the ongoing influenza pandemic 2009.

H. Fleury, S. Burrel, M. Lafon, 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network.

H. Fleury, P. Roques, F. Damond, 2000, AIDS.

Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.

B. Masquelier, D. Neau, J. Ragnaud, 2001 .

Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy

B. Masquelier, D. Neau, P. Morlat, 2008, AIDS.

Susceptibility to etravirine of HIV type 1 subtype C isolates from nevirapine/efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.

H. Fleury, P. Pinson, A. Deshpande, 2012, AIDS research and human retroviruses.

Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals.

H. Fleury, P. Bellecave, S. Reigadas, 2014, AIDS research and human retroviruses.

In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir.

H. Fleury, C. Calmels, P. Bellecave, 2014, International journal of antimicrobial agents.

Presence of drug resistance mutations among drug-naive patients in Morocco.

H. Fleury, H. Annaz, S. Mrani, 2011, AIDS research and human retroviruses.

Detection of HCV-RNA in saliva of patients with chronic hepatitis C.

P. Couzigou, H. Fleury, F. Dumas, 1993, Gut.